PegBio Co., Ltd.
Research PegBio Co., Ltd. (2565.HK) on Bullrun: market cap HKD 1.57B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2565.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.57B
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 208.36M
- Free cash flow-CNY 155.57M
Valuation Snapshot
latest market cap is HKD 1.57B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 208.36M | -CNY 155.57M | n/a | -0.55 | CNY 467.54M | CNY 93.61M | CNY 448.49M |
| FY2024 | CNY 0 | -CNY 283.16M | -CNY 184.53M | n/a | -1.01 | CNY 28.39M | CNY 101.49M | CNY 52.19M |
| FY2023 | CNY 0 | -CNY 279.00M | -CNY 233.90M | n/a | -1 | CNY 77.15M | CNY 68.91M | CNY 189.88M |
| FY2022 | CNY 0 | -CNY 306.42M | -CNY 174.58M | n/a | -1.1 | CNY 60.30M | CNY 24.16M | CNY 299.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.57B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About PegBio Co., Ltd.
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PegBio Co., Ltd.'s market cap?
PegBio Co., Ltd.'s market capitalization is HKD 1.57B.
What does PegBio Co., Ltd. do?
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity.